Skip to content
TriangleGet started
← Back to the explorer

Study reference · NCT02296125

FLAURA

Osimertinib versus earlier EGFR medicines: final overall survival

Fixed release · explorer-2026-09-11

At three years, estimated overall survival was 54% with osimertinib and 44% with gefitinib or erlotinib.

Estimated survival at 3 years

Overall survival · percentage alive in each trial group

Osimertinib54%

Study group: 279 participants · 95% confidence interval 48%–60%

Gefitinib or erlotinib44%

Study group: 277 participants · 95% confidence interval 38%–50%

The small black line shows uncertainty (95% confidence interval), where available. These estimates describe study groups, not an individual’s chance of survival.

Overall-survival hazard ratio: 0.80 (95.05% CI 0.64–1.00), osimertinib versus gefitinib or erlotinib.

Grade 3 or higher adverse events from any cause

Final overall-survival report. Lower percentages mean fewer reported severe events.

Osimertinib42%

See the safety population below.

Gefitinib or erlotinib47%

See the safety population below.

279 osimertinib; 277 gefitinib or erlotinib participants in the safety analysis.

Put the research in context

Who was studied?

Compare the reported population with what you know. It is fine to be unsure—those are useful questions for your care team.

Read the original sources →
Previously untreated advanced NSCLC with an EGFR exon 19 deletion or L858R mutation;
WHO performance status 0–1.

These are reported population details, not a complete list of eligibility criteria. Who could enroll, who participated, and whose results were analyzed can differ. This checklist does not score your match, recommend treatment, or determine trial eligibility.

Your selections and question stay on this page only. They are not saved or sent to Triangle. Copy your note before leaving; refreshing clears it.

Study design & endpoints

Double-blind, randomized phase 3 trial; 556 participants.

Primary: progression-free survival. This report is the final analysis of the secondary overall-survival endpoint.

What the chart cannot tell you

  • The comparator combines gefitinib and erlotinib. These are earlier EGFR-targeted treatments.
  • Crossover to osimertinib was allowed after progression with a confirmed T790M mutation.
  • The hazard-ratio confidence level was 95.05%, as specified in the report. Harms include events from any cause.

Results are group estimates, not a personalized forecast, treatment recommendation, or confirmation of trial eligibility.

Full results table
FLAURA: results as recorded in this release
GroupEfficacy nMedian overall survival, months (CI)Survival at 3 years (95% CI)Severe events
Osimertinib27938.6 (34.5–41.8)54% (48–60%)42%
Gefitinib or erlotinib27731.8 (26.6–36.0)44% (38–50%)47%

Grade 3 or higher adverse events from any cause. 279 osimertinib; 277 gefitinib or erlotinib participants in the safety analysis.

Median survival is a time point, not average lifespan. Confidence levels and analysis details are reported with the source.

Keep exploring

FLAURA2 →